| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10044552 | HBV | ENSG00000169083.18 | protein_coding | AR | Yes | No | 367 | A0A087WUX9 P10275 |
| TVIS10052789 | HBV | ENSG00000169083.18 | protein_coding | AR | Yes | No | 367 | A0A087WUX9 P10275 |
| TVIS30073184 | HIV | ENSG00000169083.18 | protein_coding | AR | Yes | No | 367 | A0A087WUX9 P10275 |
| TVIS44024288 | HTLV-1 | ENSG00000169083.18 | protein_coding | AR | Yes | No | 367 | A0A087WUX9 P10275 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | AR |
|---|---|
| DrugBank ID | DB00665 |
| Drug Name | Nilutamide |
| Target ID | BE0000132 |
| UniProt ID | P10275 |
| Regulation Type | antagonist |
| PubMed IDs | 3071951; 3320565; 6374639; 11752352; 20541672; 12497048; 12497018; 12496872; 16986000 |
| Citations | Raynaud JP: Antiandrogens in combination with LH-RH agonists in prostate cancer. Am J Clin Oncol. 1988;11 Suppl 2:S132-47.@@Moguilewsky M, Bertagna C, Hucher M: Pharmacological and clinical studies of the antiandrogen Anandron. J Steroid Biochem. 1987;27(4-6):871-5.@@Raynaud JP, Bonne C, Moguilewsky M, Lefebvre FA, Belanger A, Labrie F: The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. Prostate. 1984;5(3):299-311.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Labrie F: Hormonal therapy of prostate cancer. Prog Brain Res. 2010;182:321-41. doi: 10.1016/S0079-6123(10)82014-X.@@Schasfoort EM, Van De Beek C, Newling DW: Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide. Prostate Cancer Prostatic Dis. 2001;4(2):112-117.@@Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T: Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis. 2001;4(4):196-203.@@Kolvenbag GJ, Furr BJ, Blackledge GR: Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis. 1998 Dec;1(6):307-314.@@Brawer MK, Crawford ED, Labrie F, Mendoza-Valdes A, Miller PD, Petrylak DP: Androgen deprivation and other treatments for advanced prostate cancer. Rev Urol. 2001;3 Suppl 2:S59-68. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylhydantoins |
| SMILES | CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F |
| Pathways | |
| PharmGKB | PA450632 |
| ChEMBL | CHEMBL1274 |
